Clinical trials: Vaginal Atrophy
Vaginal Atrophy
Clinical Study of the CO2RE Laser Device Performance for Vaginal Atrophy Treatments
The CO2RE laser system is a fractional CO2 laser that is FDA approved under a 510(k) K101321 for dermatologic procedures requiring ablation and coagulation of soft tissues, including the skin Eligible subjects will undergo 3…
- Trial name
- NCT02704741
- Testing
- CO2RE
- Where
- 4 sites in United States
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Syneron Medical
Menopause Related Conditions
Role of Topical Oxytocin Gel in Post-Menopausal Women
Aim of the current study: To evaluate the effect of a14 day treatment period with local intravaginal application of an oxytocin-containing gel on vaginal atrophy, psychosexual and psychological/cognitive function, and metabolic…
- Trial name
- NCT05275270
- Testing
- oxytocin gel
- Where
- Egypt
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Al-Azhar University
Vaginal Atrophy
Clinical Performance and Safety of the VITA AV Clinical System
The primary objective of this clinical investigation is to demonstrate that treatment with the VITA AV clinical system is feasible and to evaluate clinical performance and safety when used to improve the symptoms and signs of…
- Trial name
- NCT06207227
- Testing
- VITA AV Clinical System
- Where
- Georgia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- AVeta Medical
Menopause
Estrogen and the Urogenital Microbiome in GSM
This is a study of how local estrogen treatment affects the microbiome of the vagina and bladder in postmenopausal women experiencing symptoms as part of "Genitourinary Syndrome of Menopause." The goal is to understand more about…
- Trial name
- NCT03336437
- Testing
- Estradiol vaginal ring
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Pelvic Organ Prolapse, Urinary Incontinence
Vaginal Estradiol Use in Pessary Care
The primary outcome of this study compare the rate of pessary discontinuation at 6 months post-pessary fitting in women using vaginal estradiol versus those not using vaginal estradiol.
- Conditions
- Pelvic Organ Prolapse, Urinary Incontinence, Pessary Ulcer of Vagina, Vaginal Atrophy
- Trial name
- NCT05458375
- Testing
- Estradiol vaginal cream
- Where
- United States
- Volunteers
- 11 people, healthy volunteers welcome
- Sponsor
- University of South Florida
Vaginal Atrophy
A Pharmacokinetic Study of Vaginally and Intravenously Administered Oxytocin
This study aims to evaluate the uptake of oxytocin following intravaginal administration of Vagitocin 400IU over a period of 15 days and also to compare oxytocin bioavailability after vaginal and intravenous administration.
- Trial name
- NCT01975129
- Testing
- Vagitocin
- Where
- Sweden
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- PepTonic Medical AB
Atrophic Vaginitis
A Trial to Evaluate the Efficacy of Low Dose Vaginal Estrogens in the Treatment of Atrophic Vaginitis
Atrophic vaginitis is a common problem that occurs in up to 40% of postmenopausal women. The main symptoms are dryness, itching and burning in and around the vagina. These symptoms in turn can cause pain with intercourse.
- Trial name
- NCT00816556
- Testing
- Estriol, Estradiol valerate, Vanicream Lite
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Maire Mac Bride
Vulvo Vaginal Atrophy
A Twelve Week Study to Investigate the Efficacy of Femarelle®, for the Treatment of Post Menopausal Vaginal Atrophy
Based on previous data published on the SERM properties of Femarelle, the investigators hypothesized that Femarelle could be a potential treatment for Vulvo-vaginal atrophy(VVA) symptoms.
- Trial name
- NCT01502527
- Testing
- Femarelle
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Dr. Lila Nachtigall Rapid Medical Research, New York
Vaginal Atrophy, Vaginal Relaxation
Evaluation of Efficacy and Safety of Votiva for Vaginal Rejuvenation
This is a multi-site, randomized, prospective study designed to evaluate the safety and efficacy of the Votiva device headpieces through radiofrequency for vaginal rejuvenation.
- Conditions
- Vaginal Atrophy, Vaginal Relaxation, Stress Urinary Incontinence
- Trial name
- NCT03520426
- Testing
- Votiva RF
- Where
- 2 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Walden, Jennifer L., M.D.,P.L.L.C.
Vaginal Atrophy, Vulvar Atrophy
VG101 Phase I/II to Treat Vulvar and Vaginal Atrophy in Post-Menopausal Women
To conduct a prospective, randomized, blinded, placebo controlled, dose escalation clinical trial in 4 cohorts of 10 postmenopausal women (total N=40) aged 45 to 65 years with at least one menopausal vaginal symptom, vaginal pH >…
- Trial name
- NCT00453089
- Testing
- VG101
- Where
- 2 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bionovo
Vaginal Atrophy
Vaginal Estrogen on Postpartum Atrophy, Perineal Pain, and Sexual Function
Pilot randomized, placebo-controlled trial of nulliparous postpartum women with a perineal laceration following a term vaginal delivery comparing vulvovaginal atrophy symptoms between women using vaginal estrogen in the…
- Trial name
- NCT03493126
- Testing
- Estradiol
- Where
- United States
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Ohio State University
Primary Sjögren Syndrome
Effects of Primary Sjögren's Syndrome on Female Genitalia and Sexual Functions
A total of 68 women with pSS and 135 healthy female patients were included in the study. All women in the study and control groups were evaluated gynecologically, and genital findings during the examination and variables related…
- Trial name
- NCT04816370
- Testing
- FSFI
- Where
- Turkey (Türkiye)
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Ankara Education and Research Hospital
Vaginal Atrophy, Genitourinary Syndrome of Menopause
The Efficacy of Topical Vaginal Oxytocin Gel in Postmenopausal Women With Vulvovaginal Atrophy
A Phase three randomized, double-blinded, study to asses the efficacy and safety of oxytocin gel in postmenopausal women with vaginal atrophy due to Genitourinary Syndrome of Menopause GSM.
- Conditions
- Vaginal Atrophy, Genitourinary Syndrome of Menopause, Vulvar Atrophy
- Trial name
- NCT06514586
- Testing
- Oxytocin, Hydroxypropyl methylcellulose
- Where
- Egypt
- Volunteers
- 244 people, healthy volunteers welcome
- Sponsor
- Oxagon
Atrophy, Vaginal Atrophy
Prospective, Open-Label, Single-Center, Non-Comparative Study to Assess the Use of Pixel CO2 Laser System (FemiLift) in the Treatment of Vulvovaginal Atrophy (VVA) in Postmenopausal Female Subjects
The purpose of this study is to assess the use of the Alma CO2 Pixel FemiLift™ in the treatment of VulvoVaginal Atrophy (VVA) in postmenopausal female subjects.
- Conditions
- Atrophy, Vaginal Atrophy, Genital Diseases, Female
- Trial name
- NCT02747641
- Testing
- Pixel CO2 Laser System
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Alma Lasers Inc.
Vulvovaginal Atrophy
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream
Evaluation of the Acceptability and Efficacy of 10 Micrograms of Estradiol Vaginal Tablets vs Promestriene Vaginal Cream in postmenopausal women aged 45 years or older, with one or more moderate to severe symptoms of vulvovaginal…
- Trial name
- NCT04232813
- Testing
- Estradiol 10 MCG Vaginal Tablet [VAGIFEM], Promestriene Vaginal
- Where
- Spain
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Instituto Palacios
Vulvar and Vaginal Atrophy
To Study Generic Estradiol 10 mcg Vaginal Tablets in the Treatment of Vulvar and Vaginal Atrophy in Post Menopausal Women.
This is a Randomized, Parallel-Group, Placebo- Controlled, Multicenter Study to Evaluate the Therapeutic Equivalence and Safety of Estradiol Vaginal Tablets 10 mcg and Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk…
- Trial name
- NCT02668796
- Testing
- Estradiol Vaginal Tablets 10 mcg (Glenmark), Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)
- Where
- United States
- Volunteers
- 522 people, healthy volunteers welcome
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Menopause, Vaginal Atrophy
Vaginal Inflammation Markers in Postmenopausal Women With and Without Symptoms of Vaginal Inflammation
Many postmenopausal women suffer from vaginal symptoms such as dryness, itching, and painful intercourse. The underlying pathology is unknown.
- Trial name
- NCT01899612
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Atrophic Vaginitis
A Comparison of Estradiol Vaginal Cream to Estrace® Cream in 350 Postmenopausal Females With Atrophic Vaginitis
The purpose of this study is to determine the therapeutic equivalence of Mylan's estradiol vaginal cream to Estrace® cream and superiority of both products to placebo.
- Trial name
- NCT02195986
- Testing
- Estradiol Vaginal Cream, 0.01%, Estrace® 0.01% cream
- Where
- 21 sites in United States
- Volunteers
- 366 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Menopausal Urethral Atrophy, Vulvar Atrophy
Laser Vaginal Treatment for GSM
Genitourinary Syndrome of Menopause (GSM) due to low estrogen levels affects about half of post-menopausal women and may have a dramatic impact on women's quality of life.
- Trial name
- NCT04042766
- Testing
- laser vaginal treatment
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sunnybrook Health Sciences Centre
Postmenopausal Osteoporosis, Postmenopause
Study Comparing Bioequivalence of Two New Formulations of Premarin/MPA With Premarin/MPA Reference Formulation.
This study will compare the bioequivalence of two new investigational combination formulations of Premarin and medroxyprogesterone acetate (MPA) with a currently marketed formulation of Premarin and medroxyprogesterone, Prempro™.
- Trial name
- NCT00381251
- Testing
- Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer